These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 15837257)
1. Should we consider aldosterone as the primary screening target for preventing cardiovascular events? Francis GS; Tang WH J Am Coll Cardiol; 2005 Apr; 45(8):1249-50. PubMed ID: 15837257 [No Abstract] [Full Text] [Related]
2. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Catena C; Colussi G; Nadalini E; Chiuch A; Baroselli S; Lapenna R; Sechi LA Arch Intern Med; 2008 Jan; 168(1):80-5. PubMed ID: 18195199 [TBL] [Abstract][Full Text] [Related]
3. [Aldosterone blockade in essential hypertension]. Venco A; Grandi AM Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298 [TBL] [Abstract][Full Text] [Related]
4. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Karagiannis A; Tziomalos K; Kakafika AI; Athyros VG; Harsoulis F; Mikhailidis DP Endocr Relat Cancer; 2008 Sep; 15(3):693-700. PubMed ID: 18586836 [TBL] [Abstract][Full Text] [Related]
5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Dieterich HA; Wendt C; Saborowski F Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159 [TBL] [Abstract][Full Text] [Related]
10. Aldosterone and cardiovascular disease: smoke and fire. Calhoun DA Circulation; 2006 Dec; 114(24):2572-4. PubMed ID: 17159070 [No Abstract] [Full Text] [Related]
11. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial? Coca SG; Perazella MA Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977 [TBL] [Abstract][Full Text] [Related]
12. A symposium: International update--the important role of aldosterone and aldosterone antagonism in cardiovascular medicine. Based on symposia held in Brussels, Belgium and Newport Beach, California. Am J Cardiol; 1990 Jun; 65(23):1K-57K. PubMed ID: 2353664 [No Abstract] [Full Text] [Related]
19. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214 [TBL] [Abstract][Full Text] [Related]